CA2678258A1 - Treprostinil treatment for interstitial lung disease and asthma - Google Patents

Treprostinil treatment for interstitial lung disease and asthma Download PDF

Info

Publication number
CA2678258A1
CA2678258A1 CA002678258A CA2678258A CA2678258A1 CA 2678258 A1 CA2678258 A1 CA 2678258A1 CA 002678258 A CA002678258 A CA 002678258A CA 2678258 A CA2678258 A CA 2678258A CA 2678258 A1 CA2678258 A1 CA 2678258A1
Authority
CA
Canada
Prior art keywords
treprostinil
pulmonary fibrosis
pharmaceutically acceptable
kit
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002678258A
Other languages
English (en)
French (fr)
Inventor
Michael Wade
Stuart Rich
Eugene Sullivan
Robert Roscigno
Roger Jeffs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2678258A1 publication Critical patent/CA2678258A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
CA002678258A 2007-02-09 2008-02-08 Treprostinil treatment for interstitial lung disease and asthma Abandoned CA2678258A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90032007P 2007-02-09 2007-02-09
US60/900,320 2007-02-09
US94021807P 2007-05-25 2007-05-25
US60/940,218 2007-05-25
PCT/US2008/053467 WO2008098196A1 (en) 2007-02-09 2008-02-08 Treprostinil treatment for interstitial lung disease and asthma

Publications (1)

Publication Number Publication Date
CA2678258A1 true CA2678258A1 (en) 2008-08-14

Family

ID=39357950

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002678258A Abandoned CA2678258A1 (en) 2007-02-09 2008-02-08 Treprostinil treatment for interstitial lung disease and asthma

Country Status (7)

Country Link
US (4) US20080280986A1 (enExample)
EP (2) EP2491932A3 (enExample)
JP (2) JP2010518122A (enExample)
KR (1) KR20090117781A (enExample)
CN (2) CN101678033A (enExample)
CA (1) CA2678258A1 (enExample)
WO (1) WO2008098196A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101780092B (zh) * 2003-05-22 2012-07-04 联合治疗公司 化合物和释放前列环素类似物的方法
DE602005020269D1 (de) * 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US20070023047A1 (en) * 2005-07-26 2007-02-01 Moshe Zalsman Face mask particularly useful as medical face mask
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
WO2007134292A2 (en) 2006-05-15 2007-11-22 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
CA2710205C (en) 2007-12-17 2016-04-26 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
US8350079B2 (en) * 2008-05-08 2013-01-08 United Therapeutics Corporation Treprostinil formulation
EP2427054A4 (en) * 2009-05-07 2014-01-15 United Therapeutics Corp SOLID COMPOSITIONS BASED ON PROSTACYCLINE ANALOGS
EP2461812B1 (en) * 2009-08-07 2014-01-01 SciPharm SàRL Composition for the treatment of cystic fibrosis
EP2547341B1 (en) 2010-03-15 2016-09-14 United Therapeutics Corporation Treatment for pulmonary hypertension
KR101868166B1 (ko) 2010-06-03 2018-06-15 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 제조
US20120010159A1 (en) * 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
HUE031652T2 (en) * 2011-02-07 2017-07-28 Scipharm Sarl New composition for treating cystic fibrosis
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
US20130345471A1 (en) 2011-03-02 2013-12-26 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
BR112014003240A2 (pt) 2011-08-12 2017-03-01 Ascendis Pharma As composição de prostaciclina com liberação sustentada
KR101997939B1 (ko) * 2011-08-12 2019-07-08 아센디스 파마 에이에스 담체-연결된 트레프로스티닐 전구약물
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
ES2733998T3 (es) * 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP2943479B1 (en) 2013-01-11 2020-04-15 Corsair Pharma, Inc. Prodrugs of treprostinil
CA2905720C (en) 2013-03-14 2021-10-19 United Therapeutics Corporation Solid forms of treprostinil
CA2904598C (en) 2013-03-15 2021-10-05 United Therapeutics Corporation Salts of treprostinil
WO2014160638A1 (en) 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
DK3060041T3 (da) 2013-10-25 2021-03-22 Insmed Inc Prostacyclinforbindelser
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
CN106460059B (zh) * 2014-06-03 2021-07-13 诺华股份有限公司 肺动脉高压生物标志物
EP3164155B1 (en) * 2014-06-13 2022-02-09 United Therapeutics Corporation Treprostinil formulations
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US10632129B2 (en) 2014-12-03 2020-04-28 Steadymed Ltd. Preservative-free treprostinil formulations and methods and devices for use with same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3515430A1 (en) 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
CN108379557A (zh) * 2018-01-15 2018-08-10 吉林大学 使用白介素因子-37治疗特发性肺纤维化
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
AU2019262117C1 (en) 2018-05-02 2024-12-05 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
BR112021002200B1 (pt) 2018-09-18 2024-03-12 Eli Lilly And Company Sal erbumina de trepostinila
EP3962472A4 (en) 2019-04-29 2023-01-25 Insmed Incorporated DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF
CN114616225A (zh) 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
KR20230011929A (ko) * 2020-04-17 2023-01-25 유나이티드 쎄러퓨틱스 코포레이션 간질성 폐 질환의 치료에 사용하기 위한 트레프로스티닐
WO2021252446A1 (en) 2020-06-09 2021-12-16 United Therapeutics Corporation Fumaryl diketopiperidine prodrugs of treprostinil
US11826328B2 (en) 2020-12-14 2023-11-28 United Therapeutics Corporation Stable treprostinil prodrugs
KR20240012354A (ko) 2021-03-03 2024-01-29 유나이티드 쎄러퓨틱스 코포레이션 (e)-3,6-비스[4-(n-카보닐-2-프로페닐)아미도부틸]-2,5-디케토피페라진(fdkp)을 추가로 포함하는, 트레프로스티닐 및 이의 프로드러그의 건조 분말 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
MY106300A (en) * 1988-06-17 1995-04-29 The Wellcome Foundation Ltd Prostaglandin analoques for use in medicine
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
ES2214753T3 (es) * 1997-11-14 2004-09-16 United Therapeutics Corporation Uso de 9-desoxi-2',9-alfa-metano-3-oxa-4,5,6-trinor-3,7-(1',3'-interfenilen)-13,14-dihidro-prostaglandina f1 para tratar la enfermedad vascular periferica.
ES2296613T3 (es) * 1999-03-18 2008-05-01 Queen Mary And Westfield College Inhibidores de la sintesis de endotelina-1.
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6756047B2 (en) * 2000-05-12 2004-06-29 The University Of Toledo Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
CN101780092B (zh) 2003-05-22 2012-07-04 联合治疗公司 化合物和释放前列环素类似物的方法
WO2007134292A2 (en) * 2006-05-15 2007-11-22 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler

Also Published As

Publication number Publication date
CN102648916A (zh) 2012-08-29
CN101678033A (zh) 2010-03-24
US20130096200A1 (en) 2013-04-18
EP2491932A3 (en) 2012-12-12
US20140018431A1 (en) 2014-01-16
US20120129941A1 (en) 2012-05-24
WO2008098196A1 (en) 2008-08-14
US20080280986A1 (en) 2008-11-13
EP2491932A2 (en) 2012-08-29
KR20090117781A (ko) 2009-11-12
JP2010518122A (ja) 2010-05-27
JP2013189459A (ja) 2013-09-26
EP2120961A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
US20130096200A1 (en) Treprostinil treatment for interstitial lung disease and asthma
ES2331187T3 (es) Utilizacion de treprostinil para mejorar las funciones renales.
ES2670711T3 (es) Receptor soluble del activador de plasminógeno de tipo uroquinasa (suPAR) como marcador de diagnóstico de inflamación de grado bajo
JP4723476B2 (ja) 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療
US4762820A (en) Therapeutic treatment for congestive heart failure
Delclaux et al. Factors associated with dyspnea in adult patients with sickle cell disease
KR102010793B1 (ko) 산소 부족 및 공기압 감소에 인한 고산병의 폐 형태의 치료를 위한 약학 조성물
CN103328506A (zh) 用于改善肺功能的疗法
US20140322226A1 (en) Acth for treatment of acute respiratory distress syndrome
Chon et al. Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome
CN115867575A (zh) 用il-33轴结合拮抗剂治疗急性呼吸窘迫综合征
CN106413740A (zh) 用于降低gdf‑15的serelaxin应用
Hulks et al. Influence of elevated plasma levels of atrial natriuretic factor on bronchial reactivity in asthma
EP4233851A1 (en) A soluble guanylat cyclase activator for treating chronic vascular dysfunction
Gao et al. Diterpenoid DGT alleviates atopic dermatitis–like responses in vitro and in vivo via targeting IL-4Rα
US20130115640A1 (en) ACTH for Treatment of Kidney Disease
US20250387391A1 (en) A soluble guanylat cyclase activator for treating chronic vascular dysfunction
WO2008137533A1 (en) Methods and compositions for upregulation of gata activity
US20260041656A1 (en) Treating pulmonary hypertension based on novel biomarker
Karsentya et al. SESSION PL ENIERE: METABOLISMES, DU GENE AU PATIENT
Yao et al. Aerobic exercise intervention improves angiotensin Ⅱ-induced cardiac remodeling by inhibiting RBP4-STRA6-Wnt/β-catenin pathway
Leggate The IL-6 system and its interaction with chronic low-grade inflammation and high intensity intermittent exercise
Mandel et al. Prospective studies of thyroid function in patients receiving gold therapy
RU2308264C2 (ru) Способ профилактики и/или лечения астмы с использованием рврв
TW201601741A (zh) 用於治療ｅｓｒｄ病患之ｐｅｗ的肌肉生長抑制素拮抗劑

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121206

FZDE Discontinued

Effective date: 20161011